On Thursday, Alpha Tau Medical Ltd. (NASDAQ:DRTS) maintained its Overweight rating and a $7.00 stock price target from Piper Sandler. The company reported its second-quarter results, which included an operating loss of $9.1 million, slightly higher than the expected $8.9 million by analysts. Despite this, the cash burn during the quarter was relatively low at approximately $7 million.
The firm noted that Alpha Tau Medical's pivotal U.S. trial is progressing, with full enrollment anticipated by the end of the year. Additionally, there is confidence in completing enrollment for the company's pancreatic feasibility studies, with data expected to be released in the first quarter of 2025. The clinical advancements are moving forward even as the company keeps its cash burn under control.
Piper Sandler highlighted that the company's cash burn in the second quarter was less than $7 million, which is considered low given the number of clinical trials in progress and the commercial readiness activities that are currently underway. The financial management of Alpha Tau Medical is seen as a positive sign for its operational efficiency.
Looking ahead, Piper Sandler expressed optimism about the company's lead indication for recurrent cutaneous squamous cell carcinoma (cSCC), which is on track for FDA submission in the second half of 2025. This timeline aligns with the firm's projections for Alpha Tau Medical to start generating revenue in 2026.
In summary, Piper Sandler reaffirmed its positive stance on Alpha Tau Medical, reiterating an Overweight rating and maintaining the $7 price target. The company's careful financial management and the progression of its clinical trials were key points in the firm's outlook.
In other recent news, Alpha Tau Medical has been the focus of Piper Sandler's latest analysis. The firm maintained its Overweight rating on the company, following a review of Alpha Tau Medical's first quarter results.
The medical device company reported an operating loss of $8.4 million, a figure notably lower than the anticipated $9.8 million loss predicted by Wall Street analysts. Alpha Tau Medical also disclosed a consistent and low cash burn rate of approximately $4 million.
In terms of clinical trials, the company showed steady progress, particularly in its ReSTART U.S. pivotal trial for recurrent cutaneous squamous cell carcinoma and a Canadian pancreatic cancer study. Piper Sandler noted that the current trials and milestones are progressing as planned, with no significant changes since the last update.
The firm expressed confidence in Alpha Tau Medical's potential, citing the significant clinical benefits of its Alpha DaRTs technology. Despite current liquidity issues faced by investors, Piper Sandler believes those who remain patient will see attractive returns in the long run.
InvestingPro Insights
As Alpha Tau Medical Ltd. (NASDAQ:DRTS) continues to navigate through its clinical trials and operational activities, it's important to consider some key financial metrics and analyst insights that could impact investor perspectives. According to InvestingPro data, Alpha Tau Medical holds a market capitalization of approximately $147.27 million.
Despite the challenges mentioned, the company's liquid assets exceed its short-term obligations, providing some financial cushioning. However, the company is not currently profitable, with an operating loss of $35.46 million over the last twelve months as of Q1 2024 and a negative return on assets of -26.5% for the same period.
InvestingPro Tips suggest that while Alpha Tau Medical holds more cash than debt on its balance sheet, it is quickly burning through cash and suffers from weak gross profit margins. Analysts do not anticipate the company will be profitable this year, and it does not pay dividends to shareholders.
These insights, along with the fact that Alpha Tau Medical has not been profitable over the last twelve months, provide a comprehensive view of the company's financial health. For investors seeking more in-depth analysis, there are additional tips available on InvestingPro, offering a more granular look at Alpha Tau Medical's financial status and future prospects.
It is also noteworthy that the company's price is at 49.65% of its 52-week high, reflecting the market's reaction to its operational progress and financial management. With a fair value estimate of $8.5 from analysts and an InvestingPro fair value of $2.14, investors are presented with divergent views on the company's valuation. As Alpha Tau Medical marches towards its FDA submission and potential revenue generation, these financial insights and analyst tips could prove pivotal for investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.